By: Colby Stong
Continuous high-dose abrocitinib and variable-dose abrocitinib are associated with long-term efficacy in patients with moderate to severe atopic
Colby Stong is a freelance medical writer and editor based in central Pennsylvania. With extensive experience in medicine and healthcare, he covers a range of topics including immunology, oncology, and dermatology, as well as healthcare technology and alternative medicine. Colby's work has been featured in numerous publications, including MDEdge, The Clinical Advisor, and Psychiatry Advisor.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
Colby's coverage focuses heavily on medical research, specifically citing data in the healthcare and pharmaceutical industries. Pitches should offer fact-based insights from reputable sources within these fields.
Given Colby’s emphasis on scientific topics and medical breakthroughs, he is likely to be interested in pitches that provide new data or research findings related to the covered areas such as cardiology, oncology, dermatology, and other medical specialties.
As there is no specific geographic focus indicated, it appears that Colby may cover global developments in healthcare and pharmaceuticals rather than focusing on a particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .